依普利酮的适应症有什么呢？

What are the indications? Eplerenone is a new type of selective aldosterone receptor antagonist that was approved for clinical use by the US Food and Drug Administration in 2002. There are two indications for eplerenone:

1. Congestive heart failure after acute myocardial infarction: Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that eplerenone can also be used for congestive heart failure after acute myocardial infarction;

2. Anti-hypertensive: Eplerenone can be used alone or in combination with other anti-hypertensive drugs for the treatment of hypertension.

Eplerenone was developed by Pfizer/Pharmacia with the trade name Inspra. It is a new generation of selective aldosterone antagonist. Eplerenone has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Its outstanding advantage is that for severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. For patients with severe heart failure and myocardial infarction, eplerenone combined with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve quality of life and reduce mortality.

Clinical trials have shown that (eplerenone) can reduce the total mortality of the treatment group by 15% in the treatment of heart failure after acute myocardial infarction when used in combination with standard treatment drugs; eplerenone is as effective as enalapril in reversing left ventricular hypertrophy and hypertension, has fewer cough side effects, and the combined effect is more obvious; eplerenone has fewer adverse reactions, except for the adverse reaction of elevated blood potassium, other adverse reactions are no different from the placebo group; there are almost no sex hormone-related side effects of spironolactone.